RN Mobile Menu

Search form


Rheumatology Network

Review, Review, Review

It is imperitive that physicians review medications with fracture patients. Various medication classes post a risk of repeat fracture. (©CatherineLall/Shutterstock.com)

Recent Content

“Not treating patients with osteoporosis drugs after a fracture would be like discharging a patient after a myocardial infarction without drugs to prevent a subsequent infarction,” researchers write in JAMA Internal Medicine.


Improving care for high-need, high-cost patients is an imperative for patients and the healthcare system. Programs are in development, NEJM perspective reports.


A NEJM study of three clinical trials for ixekizumab to treat mild to moderate psoriasis, shows that the IL-17A inhibitor performs well through 60 weeks.


To better understand Mendelian randomization and how it touches rheumatological conditions, researchers have analyzed existing results revealing a causal relationship.


Cushingoid appearance is a side effect of glucocorticoid use, but to date, there has been little knowledge about how glucocorticoids can change fat mass and redistribution.


Triple therapy in RA is infrequent, despite mounting evidence that this more cost-effective option might be as effective as treatment intensification with biologic disease-modifying antirheumatic drugs.


Rheumatoid arthritis patients who are in remission or have stable low disease activity should continue TNFi therapy to control flares, study finds.

By clicking Accept, you agree to become a member of the UBM Medica Community.